



Medi-Cal Rx

# Wegovy® Coverage Update – Temporary Continuation of Therapy Override

April 28, 2026

Effective April 1, 2026, a new Code I diagnosis restriction for Wegovy® went into effect, as announced in the alert titled [Changes to GLP-1 Drug Coverage for Wegovy®](#). Under the new Code I diagnosis restriction for Wegovy, previously approved prior authorizations (PAs) do not override **Reject Code 80 – Diagnosis Code Submitted Does Not Meet Drug Coverage Criteria**. As a result, pharmacy providers and prescribers have been required to submit a new PA request to Medi-Cal Rx for coverage consideration.

## What Pharmacy Providers and Prescribers Need to Know

Based on stakeholder feedback, and to support continuing care for impacted members, **effective April 27, 2026**, Medi-Cal Rx has implemented the following solutions:

- For members younger than 21 years of age, there will be a temporary continuation of therapy override of Reject Code 80 for Wegovy claims. This override will remain active until September 30, 2026. Claims with a date of service (DOS) on or after October 1, 2026, require an active, approved PA or an appropriate *International Classification of Diseases – 10<sup>th</sup> Revision, Clinical Modification* (ICD-10-CM) diagnosis code(s) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). The temporary continuation of therapy override for Reject Code 80 applies when all the following requirements are met:
  - The claim submitted for Wegovy has a DOS on or after April 1, 2026.
  - A paid claim is present in the member's history with a DOS on or after January 1, 2026.
- For members 21 years of age and older, approved PAs for Wegovy that were submitted on or after January 1, 2026, through March 31, 2026, will be honored through their previously approved authorization period. No further action is required of providers.

All other Medi-Cal Rx claim and utilization management (UM) edits will apply and may require submission of a PA request for coverage consideration.

## What Pharmacy Providers and Prescribers Need to Do

- For members younger than 21 years of age, resubmit to Medi-Cal Rx any previously denied claims for Wegovy with a DOS on or after April 1, 2026. If the claim denies, refer to the alert titled [How to Address Reject Code 80 – Diagnosis Code Submitted Does Not Meet Drug Coverage Criteria](#) for next steps.
  - Providers should begin submitting new PA requests to Medi-Cal Rx for coverage consideration prior to October 1, 2026, for indications that do not meet the Code I diagnosis restriction.

- For members 21 years of age and older, if the claim denies, submit a PA request for coverage considerations.
- Providers should refer to the following resources for additional information:
  - *GLP-1 Drugs for Weight Loss: Non-Benefit* section in the [Medi-Cal Rx Contract Drugs List \(CDL\)](#)
  - [Changes to GLP-1 Drug Coverage for Wegovy®](#)
  - [GLP-1 Coverage Considerations](#)
  - [Reminder: Provide Medical Justification for GLP-1 Drugs](#)

## Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at [MediCalRxEducationOutreach@primetherapeutics.com](mailto:MediCalRxEducationOutreach@primetherapeutics.com).